Cargando…
C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells
Oncolytic virus (OV) therapy is widely considered as a major breakthrough in anti-cancer treatments. In our previous study, the efficacy and safety of using C-REV for anti-cancer therapy in patients during stage I clinical trial was reported. The stimulator of interferon genes (STING)–TBK1–IRF3–IFN...
Autores principales: | Morimoto, Daishi, Matsumura, Shigeru, Bustos-Villalobos, Itzel, Sibal, Patricia Angela, Ichinose, Toru, Naoe, Yoshinori, Eissa, Ibrahim Ragab, Abdelmoneim, Mohamed, Mukoyama, Nobuaki, Miyajima, Noriyuki, Tanaka, Maki, Kodera, Yasuhiro, Kasuya, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232185/ https://www.ncbi.nlm.nih.gov/pubmed/34203706 http://dx.doi.org/10.3390/cells10061502 |
Ejemplares similares
-
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model
por: Miyajima, Noriyuki, et al.
Publicado: (2021) -
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
por: Eissa, Ibrahim Ragab, et al.
Publicado: (2018) -
Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth
por: Wu, Zhiwen, et al.
Publicado: (2019) -
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
por: Abdelmoneim, Mohamed, et al.
Publicado: (2022) -
The Impact of Metformin on Tumor-Infiltrated Immune Cells: Preclinical and Clinical Studies
por: Abdelmoneim, Mohamed, et al.
Publicado: (2023)